Mirae Asset Global Investments’s Phathom Pharmaceuticals PHAT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$38.7K Sell
3,567
-543
-13% -$6.2K ﹤0.01% 1397
2026
Q1
$45.7K Buy
4,110
+653
+19% +$8.25K ﹤0.01% 1312
2025
Q4
$57.4K Buy
3,457
+714
+26% +$10.2K ﹤0.01% 1367
2025
Q3
$32.3K Buy
2,743
+46
+2% +$475 ﹤0.01% 1421
2025
Q2
$25.9K Buy
2,697
+409
+18% +$2.26K ﹤0.01% 1359
2025
Q1
$15.1K Buy
2,288
+9
+0.4% +$55 ﹤0.01% 1419
2024
Q4
$18.6K Sell
2,279
-191
-8% -$2.37K ﹤0.01% 1431
2024
Q3
$43.3K Buy
2,470
+722
+41% +$10.1K ﹤0.01% 1328
2024
Q2
$18.2K Sell
1,748
-12,158
-87% -$125K ﹤0.01% 1394
2024
Q1
$102K Buy
13,906
+270
+2% +$2.29K ﹤0.01% 2369
2023
Q4
$124K Buy
13,636
+95
+0.7% +$819 ﹤0.01% 2425
2023
Q3
$140K Buy
13,541
+97
+0.7% +$1.33K ﹤0.01% 2385
2023
Q2
$193K Buy
13,444
+210
+2% +$2.42K ﹤0.01% 2352
2023
Q1
$94.5K Sell
13,234
-26
-0.2% -$228 ﹤0.01% 2456
2022
Q4
$149K Buy
+13,260
New +$137K ﹤0.01% 2370
2022
Q3
Sell
-89,942
Closed -$6.7M 2649
2022
Q2
$6.7M Buy
+89,942
New +$925K 0.02% 741

Other funds holding PHAT

Mirae Asset Global Investments's PHAT Position: Q2 2026 in Review

Mirae Asset Global Investments reduced its Phathom Pharmaceuticals (PHAT) stake by 13% in Q2 2026, selling an estimated $6.2K and leaving 3,567 shares worth $38.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1397.

Mirae Asset Global Investments first reported a position in PHAT in Q2 2022 and has held it in 16 quarters since. The position peaked at $6.7M in Q2 2022. 16 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Mirae Asset Global Investments held 3,567 shares of Phathom Pharmaceuticals worth $38.7K as of Q2 2026.
  • Mirae Asset Global Investments sold 543 Phathom Pharmaceuticals shares in Q2 2026, an estimated $6.2K.
  • Phathom Pharmaceuticals made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1397 holding.
  • Mirae Asset Global Investments first reported a position in Phathom Pharmaceuticals in Q2 2022 and has held it in 16 quarters since.
  • Mirae Asset Global Investments's Phathom Pharmaceuticals position peaked at $6.7M in Q2 2022.
  • 16 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.